Results 271 to 280 of about 87,925 (315)

LINC00870 promotes imatinib resistance in gastrointestinal stromal tumor via inhibiting PIGR glycosylation modifications. [PDF]

Heliyon
Li Y, Dai Z, Cheng Z, He J, Yin Y, Liu X, Zhang J, Hu G, Chen Y, Wang X, Shao Y.   +10 more
europepmc   +1 more source

Extragastrointestinal Stromal Tumor Mimicking Appendicitis: A Case Study. [PDF]

Am J Case Rep
Martinez R, Lezcano M, Randhawa J, Aijaz S, Al Mazouni Y, Altamimi A, Camacho-Perez N, Othman F, O'Neill AM, Simon JA.   +9 more
europepmc   +1 more source

Population Pharmacokinetic and Exposure-Response Analyses for Ponatinib in the Phase 3 PhALLCON Study. [PDF]

Clin Transl Sci
Hanley MJ, Larson TR, Diderichsen PM, Largajolli A, Hui K, Srimani J, Wang B, Vorog A, Gupta N.   +8 more
europepmc   +1 more source

Atypical Femur Fracture in a Teenager on Chronic Imatinib Therapy. [PDF]

Case Rep Oncol Med
Belzarena AC, Cook JL.
europepmc   +1 more source

SHP2 inhibition and adjuvant therapy synergistically target KIT-mutant GISTs via ERK1/2-regulated GSK3β/cyclin D1 pathway. [PDF]

Clin Transl Med
He C, Yu J, Mao S, Yang S, Jiang X, Huang L, Li M, He Y, Zhang X, Xiang X.   +9 more
europepmc   +1 more source

Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia. [PDF]

Cancer Chemother Pharmacol
Mangoura SA, Abdel-Raheem MH, Eltyb HA, Molla MS, Hussein AMR.   +4 more
europepmc   +1 more source

CD19-targeted HSP90 inhibitor nanoparticle combined with TKIs reduces tumor burden and enhances T-cell immunity in murine B-cell malignancies. [PDF]

Theranostics
Qin M, Ren J, Chen X, Zhou W, Zhang S, Zhang W, Shi M, Zhang M, Liu H, Ma Y, Yang M, Ji Y.   +11 more
europepmc   +1 more source

Imatinib-induced hard palate mucosal discoloration in patients with gastrointestinal stromal tumour (GIST) and dermatofibrosarcoma protuberans (DFSP): a case series of three patients and literature review. [PDF]

Postepy Dermatol Alergol
Stawarz K, Zwolinski J, Galazka A, Gorzelnik A, Bienkowska-Pluta K, Durzynska M.   +5 more
europepmc   +1 more source

Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study. [PDF]

J Hematol Oncol
Hughes TP, Saglio G, Geissler J, Kim DW, Lomaia E, Mayer J, Turkina A, Kapoor S, Cardoso AP, Nieman B, Quenet S, Cortes JE.   +11 more
europepmc   +1 more source